Robin Feldman – författare

The allure of science has always captivated members of the legal profession. Its siren's song offers a tune of perfection and the promise of endowing law with the respect and deference from society that lawyers crave. Both the bench and the bar continually look to science to rescue them from the discomfort of difficult legal decisions, and are frequently disappointed with the results. ications of taking a vigorously democratic approach to While most authors frame problems at the intersection of law and science in terms of how rapidly scientific information changes and how frequently the legal system distorts science, this book argues that problems at the intersection of law and science flow not from the changing nature of science, but from the changing nature of law. With this in mind, the book uses examples from doctrines related to abortion, gene patenting, copyright, environmental regulation, antitrust law, the insanity defense, and other doctrines to explore the nature of law and to suggest approaches for making science work more effectively within the domain of law.

Scientific and technological innovations are forcing patent law into the spotlight and revealing its many glaring inadequacies. Take, for example, the patent case that almost shut down the BlackBerry, or the growing phenomenon of patent trolling, in which patents are acquired for the sole purpose of entrapping companies whose products relate to them. And patents on genes have everyone up in arms—and our courts confused. Robin Feldman explains why patents are causing so much trouble. The problem lies in our assumption that patents set clear boundaries for rights to an invention. In reality, they do no such thing. The very nature of inventions makes them impossible to describe unambiguously for all time. When something is so new that we do not understand yet how it works, what it is capable of doing, or how it could be applied—as is often the case in biotechnology—description is necessarily slippery. Instead of hoping for clear boundaries, and moaning when we don’t get them, Rethinking Patent Law urges lawmakers to focus on what the law can do well: craft rules that anticipate the bargaining that will occur as rights unfold. By steering clear of laws that distort the bargaining process, lawmakers can help courts answer difficult questions, such as whether genes, software, and business methods constitute patentable subject matter, whether patents in the life sciences should control inventions that have yet to be discovered, and how to resolve the battles between pharmaceutical companies and generics.

In the warped world of prescription drug pricing, generic drugs can cost more than branded ones, old drugs can be relaunched at astronomical prices, and low-cost options are shut out of the market. In Drugs, Money and Secret Handshakes, Robin Feldman shines a light into the dark corners of the pharmaceutical industry to expose a web of shadowy deals in which higher-priced drugs receive favorable treatment and patients are channeled toward the most expensive medicines. At the center of this web are the highly secretive middle players who establish coverage levels for patients and negotiate with drug companies. By offering lucrative payments to these middle players (as well as to doctors and hospitals), drug companies ensure that inexpensive drugs never gain traction. This system of perverse incentives has delivered the kind of exorbitant drug prices - and profits - that everyone loves except for those who pay the bills.

The rise of artificial intelligence is challenging the foundations of intellectual property. In AI versus IP: Rewriting Creativity, science writer Robin Feldman offers a balanced perspective as she explains how artificial intelligence (AI) threatens to erode all of intellectual property (IP) - patents, trademarks, copyrights, trade secrets, and rights of publicity. Using analogies to the Bridgerton fantasy series and the Good Housekeeping 'Seal of Approval,' Professor Feldman also offers solutions to ensure a peaceful coexistence between AI and IP. And if you've ever wanted to understand just how modern AI programs like ChatGPT, Claude, Gemini, Grok, Meta AI, and others work, AI versus IP: Rewriting Creativity explains it all in simple language, no math required. AI and IP can coexist, Feldman argues, but only if we fully understand them and only with considerable effort and forethought.

The rise of artificial intelligence is challenging the foundations of intellectual property. In AI versus IP: Rewriting Creativity, science writer Robin Feldman offers a balanced perspective as she explains how artificial intelligence (AI) threatens to erode all of intellectual property (IP) - patents, trademarks, copyrights, trade secrets, and rights of publicity. Using analogies to the Bridgerton fantasy series and the Good Housekeeping 'Seal of Approval,' Professor Feldman also offers solutions to ensure a peaceful coexistence between AI and IP. And if you've ever wanted to understand just how modern AI programs like ChatGPT, Claude, Gemini, Grok, Meta AI, and others work, AI versus IP: Rewriting Creativity explains it all in simple language, no math required. AI and IP can coexist, Feldman argues, but only if we fully understand them and only with considerable effort and forethought.

While the shockingly high prices of prescription drugs continue to dominate the news, the strategies used by pharmaceutical companies to prevent generic competition are poorly understood, even by the lawmakers responsible for regulating them. In this groundbreaking work, Robin Feldman and Evan Frondorf illuminate the inner workings of the pharmaceutical market and show how drug companies twist health policy to achieve goals contrary to the public interest. In highly engaging prose, they offer specific examples of how generic competition has been stifled for years, with costs climbing into the billions and everyday consumers paying the price. Drug Wars is a guide to the current landscape, a roadmap for reform, and a warning of what is to come. It should be read by policymakers, academics, patients, and anyone else concerned with the soaring costs of prescription drugs.